Actively Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Led by Novartis Pharmaceuticals · Updated on 2026-04-14
225
Participants Needed
50
Research Sites
869 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
CONDITIONS
Official Title
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have completed the treatment period of the CLNP023X2202, CLNP023B12301 or CLNP023B12302 study on study drug
You will not qualify if you...
- Severe concurrent co-morbidities such as advanced cardiac disease (NYHA class IV) or severe pulmonary arterial hypertension (WHO class IV) that may prevent safe study participation
- Active systemic bacterial, viral, or fungal infection within 14 days prior to screening or fever ≥ 38°C (100.4°F) within 7 days prior to screening
- History or current diagnosis of ECG abnormalities that pose significant safety risks
- History of HIV or any other immunodeficiency disease
- Any illness or medical condition that investigator and sponsor believe may prevent safe tolerability or compliance with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 50 locations
1
Childrens Hospital Colorado
Aurora, Colorado, United States, 80045
Actively Recruiting
2
Georgia Nephrology Research Inst
Lawrenceville, Georgia, United States, 30046
Actively Recruiting
3
University of Iowa Health Care
Iowa City, Iowa, United States, 52242-1091
Actively Recruiting
4
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
5
Col Uni Med Center New York Presby
New York, New York, United States, 10032
Actively Recruiting
6
Novartis Investigative Site
CABA, Buenos Aires, Argentina, C1425AGC
Actively Recruiting
7
Novartis Investigative Site
Buenos Aires, Argentina, W3400ABH
Actively Recruiting
8
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil, 30150-221
Actively Recruiting
9
Novartis Investigative Site
Recife, Pernambuco, Brazil, 50740-900
Actively Recruiting
10
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil, 90035-074
Actively Recruiting
11
Novartis Investigative Site
Botucatu, São Paulo, Brazil, 3880-1001
Actively Recruiting
12
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 04038-002
Actively Recruiting
13
Novartis Investigative Site
Salvador, Brazil, 40323-010
Actively Recruiting
14
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2C4
Active, Not Recruiting
15
Novartis Investigative Site
Beijing, China, 100034
Actively Recruiting
16
Novartis Investigative Site
Shanghai, China, 200040
Actively Recruiting
17
Novartis Investigative Site
Prague, Czechia, 128 08
Active, Not Recruiting
18
Novartis Investigative Site
Montpellier, France, 34295
Actively Recruiting
19
Novartis Investigative Site
Paris, France, 75015
Actively Recruiting
20
Novartis Investigative Site
Toulouse, France, 31054
Actively Recruiting
21
Novartis Investigative Site
Erlangen, Germany, 91054
Active, Not Recruiting
22
Novartis Investigative Site
Essen, Germany, 45147
Actively Recruiting
23
Novartis Investigative Site
Hamburg, Germany, 20246
Actively Recruiting
24
Novartis Investigative Site
Mainz, Germany, 55131
Actively Recruiting
25
Novartis Investigative Site
Heraklion Crete., Greece, 715 00
Actively Recruiting
26
Novartis Investigative Site
Thessaloniki, Greece, 546 42
Actively Recruiting
27
Novartis Investigative Site
Petah Tikva, Israel, 4920235
Actively Recruiting
28
Novartis Investigative Site
Petah Tikva, Israel, 4941492
Actively Recruiting
29
Novartis Investigative Site
Ranica, BG, Italy, 24020
Actively Recruiting
30
Novartis Investigative Site
Roma, Italy, 165
Actively Recruiting
31
Novartis Investigative Site
Nagoya, Aichi-ken, Japan, 4668560
Active, Not Recruiting
32
Novartis Investigative Site
Asahikawa, Hokkaido, Japan, 0788510
Active, Not Recruiting
33
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 0608543
Completed
34
Novartis Investigative Site
Takatsuki, Osaka, Japan, 5691192
Active, Not Recruiting
35
Novartis Investigative Site
Ohtsu, Shiga, Japan, 5202192
Actively Recruiting
36
Novartis Investigative Site
Hachiōji, Tokyo, Japan, 193-0998
Actively Recruiting
37
Novartis Investigative Site
Niigata, Japan, 9518520
Active, Not Recruiting
38
Novartis Investigative Site
Leiden, South Holland, Netherlands, 2333 ZA
Actively Recruiting
39
Novartis Investigative Site
Pamplona, Navarre, Spain, 31008
Actively Recruiting
40
Novartis Investigative Site
Barcelona, Spain, 08035
Active, Not Recruiting
41
Novartis Investigative Site
Madrid, Spain, 28040
Actively Recruiting
42
Novartis Investigative Site
Madrid, Spain, 28041
Actively Recruiting
43
Novartis Investigative Site
Seville, Spain, 41009
Actively Recruiting
44
Novartis Investigative Site
Bern, Switzerland, 3010
Actively Recruiting
45
Novartis Investigative Site
Köseköy, Kocaeli, Turkey (Türkiye), 41380
Actively Recruiting
46
Novartis Investigative Site
Kayseri, Melikgazi, Turkey (Türkiye), 38039
Actively Recruiting
47
Novartis Investigative Site
Ankara, Yenimahalle, Turkey (Türkiye), 06500
Actively Recruiting
48
Novartis Investigative Site
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE7 7DN
Actively Recruiting
49
Novartis Investigative Site
Cardiff, United Kingdom, CF14 4XW
Actively Recruiting
50
Novartis Investigative Site
London, United Kingdom, W12 0HS
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here